Jia Chunsong, Cui Xin, Ou Tongwen
Department of Urology, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.
Transl Androl Urol. 2024 Jan 31;13(1):64-71. doi: 10.21037/tau-23-378. Epub 2024 Jan 23.
Managing overactive bladder (OAB) symptoms in Parkinson's disease (PD) is challenging. This study aimed to investigate the medical management of OAB symptoms in patients with PD.
Patients with OAB symptoms who were newly treated with tolterodine and/or tamsulosin were screened from a database of 187 PD patients. Before treatment, the Hoehn-Yahr scale, International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), and urodynamic evaluation were evaluated. On day 21 of treatment, the IPSS and OABSS were re-evaluated. The changes of these scores and urinary symptoms were analyzed.
Seventy patients with a mean age of 62.2±7.9 years and median Hoehn-Yahr stage of 2 (IQR 2-3) were enrolled. Tolterodine, tamsulosin, and tolterodine + tamsulosin were used in 43, 20, and 7 patients, respectively. The IPSS storage symptoms (9.4±3 . 3.5±2.3) and OABSS (9±2.8 . 4.8±3.3) improved significantly after treatment (both P<0.01). However, 28 (40%) patients displayed moderate urinary symptoms, and nocturia and urgency still affected more than half of the patients after treatment.
Tolterodine and/or tamsulosin can significantly improve OAB symptoms in PD patients. Nocturia and urgency remain common after treatment.
帕金森病（PD）患者膀胱过度活动症（OAB）症状的管理具有挑战性。本研究旨在调查PD患者OAB症状的药物治疗情况。
从187例PD患者的数据库中筛选出初用托特罗定和/或坦索罗辛治疗的OAB症状患者。治疗前，评估Hoehn-Yahr分级、国际前列腺症状评分（IPSS）、膀胱过度活动症症状评分（OABSS）及尿动力学。治疗第21天，再次评估IPSS和OABSS。分析这些评分及排尿症状的变化。
纳入70例患者，平均年龄62.2±7.9岁，Hoehn-Yahr分期中位数为2（四分位间距2 - 3）。分别有43、20和7例患者使用托特罗定、坦索罗辛及托特罗定 + 坦索罗辛。治疗后IPSS储尿期症状（9.4±3.3降至3.5±2.3）和OABSS（9±2.8降至4.8±3.3）显著改善（均P<0.01）。然而，28例（40%）患者仍有中度排尿症状，治疗后夜尿症和尿急仍影响半数以上患者。
托特罗定和/或坦索罗辛可显著改善PD患者的OAB症状。治疗后夜尿症和尿急仍然常见。
